Clinical trial
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
NCT05525338
Study timeline
Study start (actual)2022-03-23Date precision: day
Registry last updated2024-05-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Drug Monitoringunresolved
Carcinoma, Non-Small-Cell Lungunresolved
Lung Cancerunresolved
Anaplastic Lymphoma Kinase Gene Mutationunresolved
Interventions
AlectinibDRUG · verified · RxNorm: alectinib
Sponsors & collaborators
University Medical Center Groningenlead sponsor
Amsterdam University Medical Centercollaborator
Erasmus Medical Centercollaborator
Maastricht University Medical Centercollaborator
Radboud University Medical Centercollaborator
The Netherlands Cancer Institutecollaborator
Leiden University Medical Centercollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05525338 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.